SEATTLE , Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m.
Rights Offering will be Available to All Stockholders of Record on February 13, 2020 $60 million expected to be raised; fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP, and New Enterprise Associates, Inc. SEATTLE , Feb.
PACIFICA Trial Protocol Amended to Allow for Primary Analysis of Spleen Volume Reduction (SVR) Rates on 168 Patients End of Study Analysis of Total Symptom Score (TSS) and Overall Survival (OS) to be Performed on 348 Patients SEATTLE , Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp.
3101 Western Ave., #800
Seattle, WA 98121
T +1 206-282-7100 T +1 800-215-2355 (US only) F +1 206-284-6206